Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP657513.RAQtFVzD1vWJTj3CxfYsgqa9cWtZ-Hhkt2HNhRjY6pKfo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP657513.RAQtFVzD1vWJTj3CxfYsgqa9cWtZ-Hhkt2HNhRjY6pKfo130_assertion type Assertion NP657513.RAQtFVzD1vWJTj3CxfYsgqa9cWtZ-Hhkt2HNhRjY6pKfo130_head.
- NP657513.RAQtFVzD1vWJTj3CxfYsgqa9cWtZ-Hhkt2HNhRjY6pKfo130_assertion description "[1) Aberrations involving p27 (KIP1), cyclin E, CDK4 and p16 (INK4A) are considered early events in HPV 16 and 18-associated cervical carcinogenesis (CINI & II), whereas cyclin D1 aberrations are late events (CINIII & ISCC) 2) Immunohistochemical tests for p16 (INK4A) and cyclin E could help in early diagnosis of cervical carcinoma 3) Only FIGO stage, cyclin D1, p27 (Kip1) and Ki-67 are independent prognostic factors that might help in predicting outcome of cervical cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP657513.RAQtFVzD1vWJTj3CxfYsgqa9cWtZ-Hhkt2HNhRjY6pKfo130_provenance.
- NP657513.RAQtFVzD1vWJTj3CxfYsgqa9cWtZ-Hhkt2HNhRjY6pKfo130_assertion evidence source_evidence_literature NP657513.RAQtFVzD1vWJTj3CxfYsgqa9cWtZ-Hhkt2HNhRjY6pKfo130_provenance.
- NP657513.RAQtFVzD1vWJTj3CxfYsgqa9cWtZ-Hhkt2HNhRjY6pKfo130_assertion SIO_000772 18301453 NP657513.RAQtFVzD1vWJTj3CxfYsgqa9cWtZ-Hhkt2HNhRjY6pKfo130_provenance.
- NP657513.RAQtFVzD1vWJTj3CxfYsgqa9cWtZ-Hhkt2HNhRjY6pKfo130_assertion wasDerivedFrom befree-2016 NP657513.RAQtFVzD1vWJTj3CxfYsgqa9cWtZ-Hhkt2HNhRjY6pKfo130_provenance.
- NP657513.RAQtFVzD1vWJTj3CxfYsgqa9cWtZ-Hhkt2HNhRjY6pKfo130_assertion wasGeneratedBy ECO_0000203 NP657513.RAQtFVzD1vWJTj3CxfYsgqa9cWtZ-Hhkt2HNhRjY6pKfo130_provenance.